Medical Center New Polyclinic Gabrovo Ltd.
- Address
- Bulevard Mogilyov 52a, 5312 Gabrovo, Bulgaria
Medical Center New Polyclinic Gabrovo Ltd.
Medical Center New Polyclinic Gabrovo Ltd. is a clinical research facility specializing in cardiovascular medicine and preventive health studies. The center demonstrates particular expertise in conducting complex phase 2 and phase 3 clinical trials for innovative therapeutics targeting hypertension and heart failure, contributing to the advancement of treatment options for patients with challenging cardiovascular conditions.
- Resistant and uncontrolled hypertension research with novel aldosterone synthase inhibitors
- Heart failure studies across the spectrum, including both reduced and preserved ejection fraction
- Long-term safety and efficacy monitoring in cardiovascular therapeutics
- Vaccine immunogenicity trials in older adult populations
The facility has extensive experience in evaluating emerging therapies for heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF), utilizing biomarkers such as NT-proBNP to assess therapeutic response. Additionally, the center conducts research in preventive medicine, including influenza immunization studies in elderly populations. Their research portfolio reflects a commitment to addressing unmet needs in cardiovascular disease management and prevention.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 therapeutic areas and 15 of 35 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG3trials
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Medical Center New Polyclinic Gabrovo Ltd.
lock Showing 1 of 14 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Effect of Orforglipron on Major Adverse Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease | Eli Lilly & Co. | Phase III | Recruiting | May 2026 | — |
IMP list
lock Showing 1 of 35 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Bi 690517 | 2 | Unknown | 2025-08-22 | 2025-10-15 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.